Global CNS Disorders Drug Market is expected to grow at a CAGR of 4.2% from 2015 to 2019

Date: 2016-09-12

The central nervous system drug industry is the second largest therapeutic industry, accounting for a total market value of USD 58.4 billion in 2014. Central nervous system drugs comprise of group of those drugs for producing both psychological and physiological effects through different types of mechanisms.

Throughout the central nervous disorders system drugs market, antidepressants, antipsychotics and antiepileptics jointly occupy the largest market share.

Global CNS Disorders Drug Market Share Analysis, by Types, 2014


Antipsychotics are central nervous system therapies used to treat diseases such as schizophrenia or bipolar disorder. Patients with schizophrenia may hear “voices” or have strange thoughts that are “out of touch” with reality that can hamper their ability to carry out normal day-to-day life. Patients with bipolar disorder are characterized by mood changes that cycle between “high” manic moments and “low” depression moments. Together, the antipsychotic and antimaniac drug markets represent approximately 5 million people and generated revenues of USD 14.5 billion in 2014, a decline of 3.2% from 2013 largely driven by increased competition from lower priced generic drugs.

Antidepressants are central nervous system therapies used to treat diseases such as major depressive disorder (MDD), dysthymic disorder, and seasonal affective disorder. MDD is a condition that lasts 2 weeks or more, and interferes with a person’s ability to carry on daily tasks and enjoy activities that previously brought pleasure.  Depression affects an estimated 121 million people worldwide, and the antidepressant market to treat depression generated revenues of almost USD14.8 billion in 2014.

Antiepileptics are therapies designed to treat patients with epilepsy, a brain disorder in which clusters of nerve cells signal abnormally, which can lead to seizures. Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of $15.5 billion in healthcare. Epilepsy can be treated through both surgical and pharmaceutical intervention, and the market for pharmaceutical treatment of epilepsy generated USD 8.3 billion in 2014.

The global CNS disorders drug market is expected to grow at a CAGR of 4.2% from 2015 to 2019. Some of the major players in the market are Eli Lilly (U.S.), AstraZeneca (UK), Wyeth (U.S.), Johnson & Johnson (U.S.), Pfizer (U.S.), Forest Laboratories (U.S.), Bristol-Meyers Squibb (U.S.) and so on.

Read Full Report:

Joanna | Executive – International Business and partner Relations
E-mail: | Tel: 1-510-400-8520


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample